JP2024538751A5 - - Google Patents

Info

Publication number
JP2024538751A5
JP2024538751A5 JP2024521318A JP2024521318A JP2024538751A5 JP 2024538751 A5 JP2024538751 A5 JP 2024538751A5 JP 2024521318 A JP2024521318 A JP 2024521318A JP 2024521318 A JP2024521318 A JP 2024521318A JP 2024538751 A5 JP2024538751 A5 JP 2024538751A5
Authority
JP
Japan
Prior art keywords
immune cells
memory
cells
modified
human immune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024521318A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024538751A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/077721 external-priority patent/WO2023060212A1/en
Publication of JP2024538751A publication Critical patent/JP2024538751A/ja
Publication of JP2024538751A5 publication Critical patent/JP2024538751A5/ja
Pending legal-status Critical Current

Links

JP2024521318A 2021-10-06 2022-10-06 優れた適応免疫細胞の集団を促進することによる養子細胞移入の増強 Pending JP2024538751A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163253058P 2021-10-06 2021-10-06
US63/253,058 2021-10-06
PCT/US2022/077721 WO2023060212A1 (en) 2021-10-06 2022-10-06 Enhancing adoptive cell transfer by promoting a superior population of adaptive immune cells

Publications (2)

Publication Number Publication Date
JP2024538751A JP2024538751A (ja) 2024-10-23
JP2024538751A5 true JP2024538751A5 (enExample) 2025-10-15

Family

ID=83996498

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024521318A Pending JP2024538751A (ja) 2021-10-06 2022-10-06 優れた適応免疫細胞の集団を促進することによる養子細胞移入の増強

Country Status (7)

Country Link
US (1) US20240398950A1 (enExample)
EP (1) EP4412627A1 (enExample)
JP (1) JP2024538751A (enExample)
CN (1) CN118541160A (enExample)
AU (1) AU2022361057A1 (enExample)
CA (1) CA3233989A1 (enExample)
WO (1) WO2023060212A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4565684A1 (en) * 2022-08-02 2025-06-11 National University Corporation Hokkaido University Methods of improving cellular therapy with organelle complexes
JP2026523341A (ja) 2023-05-15 2026-07-14 エヌクロマ・バイオ,インコーポレーテッド Hbv遺伝子発現のエピジェネティック調節のための組成物および方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3459560B1 (en) 2011-04-08 2021-02-24 The United States of America, as represented by The Secretary, Department of Health and Human Services Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer
CA2952121A1 (en) 2014-06-13 2015-12-17 Childrens' Medical Center Corporation Products and methods to isolate mitochondria
WO2016008937A1 (en) * 2014-07-16 2016-01-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the intercellular transfer of isolated mitochondria in recipient cells
CA2964785A1 (en) * 2014-11-05 2016-05-12 Board Of Regents, The University Of Texas System Gene modified immune effector cells and engineered cells for expansion of immune effector cells
CN109983120A (zh) * 2016-11-14 2019-07-05 白雁生物技术公司 含有外源线粒体的天然杀伤细胞和含有其的药物组合物
KR20210045435A (ko) * 2018-08-14 2021-04-26 이멜 바이오테라퓨틱스, 인코포레이티드. 미토콘드리아 질환 또는 장애 및 헤테로플라스미를 치료하기 위한 방법 및 조성물
US20210261921A9 (en) * 2018-10-09 2021-08-26 The Regents Of The University Of California Mitochondrial transplantation to alter energy metabolism
EP3880213A4 (en) * 2018-11-13 2022-11-23 Abraham J and Phyllis Katz Cord Blood Foundation T CELLS WITH IMPROVED MITOCHONDRIAL FUNCTION
CN115427052A (zh) * 2020-03-31 2022-12-02 米诺维亚治疗公司 线粒体加强疗法
MX2022012157A (es) * 2020-03-31 2023-02-15 Minovia Therapeutics Ltd Celulas geneticamente modificadas enriquecidas con mitocondrias y usos de estas.
AU2021246112A1 (en) * 2020-04-03 2022-11-10 Cellvie Inc. Enhancement of adoptive cell transfer
US20240228960A1 (en) * 2021-05-18 2024-07-11 Imel Biotherapeutics, Inc. Methods and compositions for reducing immune cell exhaustion using mitochondria replacement
WO2022243906A1 (en) * 2021-05-18 2022-11-24 Imel Biotherapeutics, Inc. Methods and compositions for generating mitochondria replaced lymphoid cells

Similar Documents

Publication Publication Date Title
MacDonald et al. Methods to manufacture regulatory T cells for cell therapy
JP6031021B2 (ja) 細胞治療のためのt細胞を調製するための方法
JP2021509586A5 (enExample)
JP2018531035A5 (enExample)
JP2018515108A (ja) 準静的細胞培養
JP2022191501A (ja) 多能性幹細胞からヘルパーt細胞を製造する方法
JP2019520823A5 (enExample)
JP2022501031A5 (enExample)
JP2023503061A5 (enExample)
JP2022554348A5 (enExample)
JP2019522984A5 (enExample)
Li et al. Artificial antigen-presenting cells: the booster for the obtaining of functional adoptive cells
JP2024535002A5 (enExample)
JP2025504002A5 (enExample)
JP2020191873A5 (enExample)
CN112553157A (zh) 一种淋巴细胞的扩增体系及扩增方法
JP2023530419A5 (enExample)
JPWO2021100585A5 (enExample)
CN115838432B (zh) 一种靶向调控抗原特异性t细胞的融合蛋白及应用
Shih et al. Clinical-scale 10-day TCR-T cell manufacturing using IL-2/7/15 and TGF-β promotes early memory and tissue-resident-like phenotypes and robust antitumor activity in vitro
Lim et al. A GD Type of Cancel Culture
CN119307444A (zh) 细胞治疗产品制备工艺及其应用
CN121263513A (zh) 体外衍生的t细胞群体、其生成方法及使用方法
Bézie et al. Expanded human CD8+ CD45RClowFoxp3+ Tregs secreting IFNγ, IL-10, IL-34 and TGFβinhibit human transplant rejection
Plate Effects of a cell-free helper factor (s) on the kinetics of T-cell responses to histocompatibility antigens